Prevalence and correlates of ENDS use among adults being treated for chronic lung disease
- Publisher: E.U.E.P. European Publishing
Tobacco Induced Diseases
WCTOH | Diseases of the respiratory system | RC705-779 | Neoplasms. Tumors. Oncology. Including cancer and carcinogens | RC254-282
lung disease such as asthma or COPD may be exacerbated by electronic nicotine
device (ENDS) use. Despite this, little is known about the extent to which
adults with chronic lung disease use ENDS and what factors are associated with
We analyzed data from the second wave of the Population
Assessment of Tobacco and Health (PATH) study. The PATH study recruited 28,362
U.S. adults over the age of 18 using a multi-stage randomized sampling
protocol. Our analysis was restricted to adults who reported being treated for
COPD or asthma in the past 12 months (N=1,748). Among these individuals, we
examined prevalence of ever and current ENDS use, intensity of use, and
motivations for use.
one-quarter (24.72%) of individuals being treated for COPD or asthma reported
ever using ENDS; 4.09% were established users and 3.99% were experimental users.
Established e-cigarette users were more likely to be white and younger. The
average number of puffs from an e-cigarette on the last day used was 18.05. Key
motivations for ENDS use among this population include: perceptions of less
harm to the user (79.72%) and to other people (78.84%), because they can be
used in places where people can't smoke (74.2%), perceptions that they help
people quit smoking (73.94%), perceived acceptability to non-smokers than
cigarettes (70.37%), and appealing flavors (64.0%).
significant number of individuals being treated for lung disease have or are
currently using ENDS, and many of these individuals use these products for
health-related concerns. Healthcare providers treating these patients should
ask about ENDS use and offer counseling and treatment to help these individuals
become tobacco free.